Hawaii 2023 Regular Session

Hawaii Senate Bill SR62 Compare Versions

Only one version of the bill is available at this time.

Old	New	Differences
1	1	THE SENATE S.R. NO. 62 THIRTY-SECOND LEGISLATURE, 2023 STATE OF HAWAII SENATE RESOLUTION Requesting the Department of Health to establish a beneficial treatments advisory council to review, evaluate, and recommend new medicinal mental health treatments.
2	2
3	3	THE SENATE S.R. NO. 62
4	4	THIRTY-SECOND LEGISLATURE, 2023
5	5	STATE OF HAWAII
6	6
7	7	THE SENATE
8	8
9	9	S.R. NO.
10	10
11	11	62
12	12
13	13	THIRTY-SECOND LEGISLATURE, 2023
14	14
15	15
16	16
17	17	STATE OF HAWAII
18	18
19	19
20	20
21	21
22	22
23	23
24	24
25	25
26	26
27	27
28	28
29	29	SENATE RESOLUTION
30	30
31	31
32	32
33	33
34	34
35	35	Requesting the Department of Health to establish a beneficial treatments advisory council to review, evaluate, and recommend new medicinal mental health treatments.
36	36
37	37
38	38
39	39
40	40
41	41	WHEREAS, mental health conditions are treated in various ways depending on the condition, including with medication, therapy, and psychosocial services; and WHEREAS, these treatments are effective for certain conditions and patients but do not treat all mental health conditions; and WHEREAS, research supports natural and alternative medicines and therapies as safe and effective methods for treating depression, post-traumatic stress disorder, addiction, end-of-life psychological distress, and other afflictions; and WHEREAS, due to their efficacy in treating treatment-resistant depression and post-traumatic stress disorder, methylenedioxymethamphetamine (MDMA) and psilocybin have each been granted breakthrough therapy designation status, which fast-tracks research and potential approval of treatments, by the United States Food and Drug Administration; now, therefore, BE IT RESOLVED by the Senate of the Thirty-second Legislature of the State of Hawaii, Regular Session of 2023, that the Department of Health is requested to establish a Beneficial Treatments Advisory Council; and BE IT FURTHER RESOLVED that the Beneficial Treatments Advisory Council is requested to examine: (1) Federal, state, and local laws, regulations, administrative rules, and procedures regarding medicinal mental health treatments; (2) Existing medical, psychological, and scientific studies, research, and information relating to the safety and efficacy of medicinal mental health treatments; and (3) Requirements, specifications, and guidelines for a medical professional to prescribe and provide various medicinal treatments to patients in jurisdictions where the treatment is used for mental health conditions; and BE IT FURTHER RESOLVED that the Beneficial Treatments Advisory Council is requested to develop a long-term strategic plan to ensure the safe, accessible, and affordable availability of therapeutic psilocybin, psilocybin-based products, and MDMA for adults ages twenty-one years old and older; and BE IT FURTHER RESOLVED that the following individuals, or their respective designees, are requested to serve as members of the Beneficial Treatments Advisory Council: (1) The Executive Director of the Office of Wellness and Resilience, who is requested to serve as chair; (2) The Attorney General; (3) The Chairperson of the State Council on Mental Health; (4) One physician licensed pursuant to chapter 453, Hawaii Revised Statutes, or advanced practice registered nurse licensed pursuant to chapter 457, Hawaii Revised Statutes, with prescriptive authority to prescribe and administer psychotropic medication, to be invited by the chair; (5) One physician licensed pursuant to chapter 453, Hawaii Revised Statutes, with specialties in substance abuse and psychiatry, to be invited by the chair; (6) One representative from an organization that advocates for the therapeutic use of plant-based psychedelic modalities, to be invited by the chair; (7) One representative from an accredited research institution that certifies and trains professionals on the use of psychedelic modalities, to be invited by the chair; and (8) Any other person that may be invited by the chair to serve on the working group; and BE IT FURTHER RESOLVED that the members of the Beneficial Treatments Advisory Council are requested to serve without compensation but with reimbursement for expenses, including travel expenses, necessary for the performance of their duties; and BE IT FURTHER RESOLVED that the Beneficial Treatments Advisory Council is requested to submit: (1) A preliminary report of its findings and recommendations to the Legislature no later than twenty days prior to the convening of the Regular Session of 2024; and (2) A final report of its findings and recommendations, including any proposed legislation, to the Legislature no later than twenty days prior to the convening of the Regular Session of 2025; and BE IT FURTHER RESOLVED that the Beneficial Treatments Advisory Council is requested to dissolve on July 1, 2025; and BE IT FURTHER RESOLVED that certified copies of this Resolution be transmitted to the Director of Health, Executive Director of the Office of Wellness and Resilience, Attorney General, and Chairperson of the State Council on Mental Health. OFFERED BY: _____________________________ Report Title: Beneficial Treatments Advisory Council; Department of Health; Reports
42	42
43	43	WHEREAS, mental health conditions are treated in various ways depending on the condition, including with medication, therapy, and psychosocial services; and
44	44
45	45
46	46
47	47	WHEREAS, these treatments are effective for certain conditions and patients but do not treat all mental health conditions; and
48	48
49	49
50	50
51	51	WHEREAS, research supports natural and alternative medicines and therapies as safe and effective methods for treating depression, post-traumatic stress disorder, addiction, end-of-life psychological distress, and other afflictions; and
52	52
53	53
54	54
55	55	WHEREAS, due to their efficacy in treating treatment-resistant depression and post-traumatic stress disorder, methylenedioxymethamphetamine (MDMA) and psilocybin have each been granted breakthrough therapy designation status, which fast-tracks research and potential approval of treatments, by the United States Food and Drug Administration; now, therefore,
56	56
57	57
58	58
59	59	BE IT RESOLVED by the Senate of the Thirty-second Legislature of the State of Hawaii, Regular Session of 2023, that the Department of Health is requested to establish a Beneficial Treatments Advisory Council; and
60	60
61	61
62	62
63	63	BE IT FURTHER RESOLVED that the Beneficial Treatments Advisory Council is requested to examine:
64	64
65	65
66	66
67	67	(1) Federal, state, and local laws, regulations, administrative rules, and procedures regarding medicinal mental health treatments;
68	68
69	69
70	70
71	71	(2) Existing medical, psychological, and scientific studies, research, and information relating to the safety and efficacy of medicinal mental health treatments; and
72	72
73	73
74	74
75	75	(3) Requirements, specifications, and guidelines for a medical professional to prescribe and provide various medicinal treatments to patients in jurisdictions where the treatment is used for mental health conditions; and
76	76
77	77
78	78
79	79	BE IT FURTHER RESOLVED that the Beneficial Treatments Advisory Council is requested to develop a long-term strategic plan to ensure the safe, accessible, and affordable availability of therapeutic psilocybin, psilocybin-based products, and MDMA for adults ages twenty-one years old and older; and
80	80
81	81
82	82
83	83	BE IT FURTHER RESOLVED that the following individuals, or their respective designees, are requested to serve as members of the Beneficial Treatments Advisory Council:
84	84
85	85
86	86
87	87	(1) The Executive Director of the Office of Wellness and Resilience, who is requested to serve as chair;
88	88
89	89
90	90
91	91	(2) The Attorney General;
92	92
93	93
94	94
95	95	(3) The Chairperson of the State Council on Mental Health;
96	96
97	97
98	98
99	99	(4) One physician licensed pursuant to chapter 453, Hawaii Revised Statutes, or advanced practice registered nurse licensed pursuant to chapter 457, Hawaii Revised Statutes, with prescriptive authority to prescribe and administer psychotropic medication, to be invited by the chair;
100	100
101	101
102	102
103	103	(5) One physician licensed pursuant to chapter 453, Hawaii Revised Statutes, with specialties in substance abuse and psychiatry, to be invited by the chair;
104	104
105	105
106	106
107	107	(6) One representative from an organization that advocates for the therapeutic use of plant-based psychedelic modalities, to be invited by the chair;
108	108
109	109
110	110
111	111	(7) One representative from an accredited research institution that certifies and trains professionals on the use of psychedelic modalities, to be invited by the chair; and
112	112
113	113
114	114
115	115	(8) Any other person that may be invited by the chair to serve on the working group; and
116	116
117	117
118	118
119	119	BE IT FURTHER RESOLVED that the members of the Beneficial Treatments Advisory Council are requested to serve without compensation but with reimbursement for expenses, including travel expenses, necessary for the performance of their duties; and
120	120
121	121
122	122
123	123	BE IT FURTHER RESOLVED that the Beneficial Treatments Advisory Council is requested to submit:
124	124
125	125
126	126
127	127	(1) A preliminary report of its findings and recommendations to the Legislature no later than twenty days prior to the convening of the Regular Session of 2024; and
128	128
129	129
130	130
131	131	(2) A final report of its findings and recommendations, including any proposed legislation, to the Legislature no later than twenty days prior to the convening of the Regular Session of 2025; and
132	132
133	133
134	134
135	135	BE IT FURTHER RESOLVED that the Beneficial Treatments Advisory Council is requested to dissolve on July 1, 2025; and
136	136
137	137
138	138
139	139	BE IT FURTHER RESOLVED that certified copies of this Resolution be transmitted to the Director of Health, Executive Director of the Office of Wellness and Resilience, Attorney General, and Chairperson of the State Council on Mental Health.
140	140
141	141
142	142
143	143
144	144
145	145
146	146
147	147	OFFERED BY: _____________________________
148	148
149	149
150	150
151	151	OFFERED BY:
152	152
153	153	_____________________________
154	154
155	155
156	156
157	157
158	158
159	159	Report Title:
160	160
161	161	Beneficial Treatments Advisory Council; Department of Health; Reports